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Summary
QUESTIONS UNDER STUDY: Mannan-binding lectin
(MBL) and MBL-associated serine protease-2 (MASP-2)
are two key components of the lectin-pathway of
complement-activation. Information on the potential role
of lectin-pathway components in carcinogenesis versus im-
mune surveillance of cancer is scarce. This study aimed to
determine if serum concentrations of MBL and MASP-2
differ between children with cancer and healthy age-
matched controls.
METHODS: In this retrospective multicentre study, MBL
and MASP-2 were measured by commercially available
ELISA in frozen remnants of serum taken at diagnosis in
paediatric patients with cancer. For six diagnostic groups,
these concentrations were compared with serum concentra-
tions of age-matched healthy controls using exact Wilcox-
on signed-rank tests.
RESULTS: MBL and MASP-2 were measured in serum of
372 patients. MBL was significantly higher in patients with
solid tumours vs. controls (median, 2,799 vs. 1,917 μg/L; P
= 0.008), and MASP-2 was significantly higher in patients
with acute lymphoblastic leukaemia (406 vs. 317 μg/L; P
= 0.009), Non-Hodgkin lymphoma (361 vs. 293 μg/L; P =
0.037) and CNS tumors (463 vs. 296 μg/L; P = 0.002).
CONCLUSIONS: These results may indicate a role of
MBL and MASP-2 in the initiation or progression of spe-
cific paediatric cancers, while other mechanisms remain
possible as well. Larger, disease-specific studies are war-
ranted for confirmation and for elucidation of the underly-
ing mechanisms.
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Introduction
In contrast to adaptive immunity and to certain components
of innate immunity, only little is known on the influence of
the complement system on cancer suppression and promo-
tion [1, 2]. The lectin pathway of complement activation is
an important part of innate immunity. It is mainly involved
in opsonisation and lysis of pathogens and in recruitment
of inflammatory cells. Mannan-binding lectin (MBL) binds
mannose and N-acetylglucosamine structures on the sur-
face of pathogens and builds complexes with MBL-associ-
ated serine protease (MASP-2). Bound to MBL or ficolins,
MASP-2 activates the complement system cascade by gen-
erating the C3 convertase C4bC2b [3]. Due to single nuc-
leotide polymorphisms, deficiencies of MBL and MASP-2,
two key components of the lectin pathway, are frequent in
Caucasians, with an incidence of about 10% [3]. In adults,
such deficiencies or the underlying genotypes seem to be
associated with the incidence, or the prognosis, of differ-
ent types of carcinoma both for MBL [4–8] and MASP-2
[9, 10]. In young children, where adaptive immunity is
still maturing, innate immunity may play a more important
role in carcinogenesis or immunosurveillance. Despite this,
nearly nothing is known on components of the lectin path-
way in children with cancer. We are aware of only one ex-
ception, a study on MBL genotypes in children with acute
lymphoblastic leukaemia (ALL), who were found to have
an increased frequency of low-producing MBL genotype
compared to healthy adults [11]. The role of MASP-2, and
of MBL phenotypes, in children with cancer versus healthy
controls has not yet been studied.
This study aimed to explore if serum concentrations of
MBL and MASP-2 differ between children with cancer and
healthy age-matched controls.
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Methods
Patients
In this retrospective multicentre cohort study, patients dia-
gnosed below 18 years of age, and between January 1, 2002
and December 31, 2006, at one of four participating paedi-
atric oncology centres (Bern, Bonn, Geneva, Zurich) with a
malignancy requiring chemotherapy were investigated. Pa-
tients with relapsed or second malignancies and those in
which serum was not accessible were excluded. Required
was ≥100 µL serum taken within two weeks of diagnosis
and before starting chemotherapy. This study was approved
by the respective Institutional Review Boards.
Characteristics of patients and malignancies [12] were ex-
tracted from patient charts. Diagnoses were classified into
six groups: ALL, acute myeloid leukaemia, Hodgkin’s dis-
ease, non-Hodgkin lymphoma (NHL), tumour of the cent-
ral nervous system (CNS; hereafter called CNS-tumour),
and solid tumour outside the CNS (hereafter called solid tu-
mour).
Determination of MBL and MASP-2 serum
concentrations
Remnants of patients’ serum which had been taken for clin-
ical purposes at time of diagnosis were stored at -20 °C un-
til analysis. MBL and MASP-2 serum concentrations were
measured using commercially available enzyme-linked im-
munosorbent assay (ELISA) kits according to the manu-
facturer’s instructions. The minimal detection limit was 2
μg/L for MBL (MBL oligomer ELISA kit, Antibodyshop,
Gentofte, Denmark) and 6 μg/L for MASP-2 (HK326,
HyCult, Uden, The Netherlands). The serum usually under-
went two freeze/thaw cycles, for measurement of MBL and
MASP-2, respectively. Additional freeze/thaw cycles were
needed if the first ELISA result was not valid, because it
was below or above the calibration range, or because the
coefficient of variation of the duplicate determinations ex-
ceeded the limit defined in the manufacturer’s instructions.
Controls and matching process
MBL and MASP-2 serum concentrations in children vary
substantially with age [13, 14], whereas adult serum con-
centrations are considered to be stable over time [3, 15].
Thus, patients were age-matched with healthy children
(hereafter called controls) in whom MBL and MASP-2 ser-
um concentrations had been determined using the same
ELISA kits [14]. These children had had outpatient con-
sultations at the Infectious Diseases Clinic, Department
of Paediatrics, University of Bern, Switzerland. They had
been found not to have any relevant acute or chronic infec-
tion in the last three months before consultation, and their
C-reactive protein, if determined for clinical reasons, was
below 30 mg/L [14].
Matching, allowing for a relative age difference of 20%
between patients and controls, was performed by one of the
authors (UP.F.) who was blinded for MBL and MASP-2
serum concentrations. Because of the relatively low num-
ber of controls available, the same control could be
matched to two patients within each diagnostic group.
Statistical analysis
Exact Fisher’s and Fisher-Freeman-Halton tests were used
to compare demographic characteristics. Within each dia-
gnostic group, median differences of MBL and MASP-2
between patients and controls were calculated, together
with their exact Hodges-Lehmann 95% confidence inter-
vals (CI), and exact Wilcoxon signed-rank test statistics.
Sensitivity analyses were performed in diagnostic groups
where some controls had been matched to two patients by
randomly eliminating one of the respective two patient-
control pairs. Because of heterogeneity of diagnoses, we
deliberately refrained from comparing MBL and MASP-2
serum concentrations between all patients and controls. Be-
cause of the exploratory nature of this study, we did not ap-
ply corrections for the multiple comparisons performed.
Two-sided test were used throughout. P-values <0.05 were
considered significant. The analyses were performed using
StatXact 8.0 (Cytel Software Corp., Cambridge, MA).
Results
Patients
Of 718 paediatric malignancies potentially eligible for the
study, 37 (5.2%) relapsed and 1 (0.1%) second malignancy
were excluded. Of the 680 patients with a non-relapsed ﬁrst
malignancy, 308 (43%) were excluded because sufﬁcient
serum was not accessible. While sex and age were not sig-
nificantly associated with inclusion versus exclusion, pa-
tients with CNS-tumors were less often included into the
study than those with other malignancies (46 of 127, 36%,
versus 326 of 591, 55%; table 1; further details of this
cohort have been described elsewhere [16].). Finally, 372
(52%) patients were included in the study. Their median
age at diagnosis was 7.4 years (range, 0.05 to 17.8; in-
terquartile range (IQR), 3.4 to 12.8), and 157 (42%) were
female.
The median MBL serum concentration of patients at time
of diagnosis was 2,808 μg/L (range, 2 to 10,060; IQR, 620
to 4,062). The median MASP-2 serum concentration was
391 μg/L (range, 46 to 2,771; IQR, 247 to 591). Sex and
duration of serum storage were not significantly associated
with MBL and MASP-2 [16].
Controls
The median age of 120 controls available for matching was
3.4 years (range, 0.06 to 14.7, IQR, 1.2 to 7.2), 62 (52%)
of them were female. While the sex distribution was thus
comparable between controls and patients studied, the con-
trols had a significantly different age distribution (table 1).
The median serum concentration of controls was 2,110
μg/L (range, 8 to 7,957; IQR, 441 to 3,389) for MBL, and
334 μg/L (range, <12.5 to 1,980; IQR, 231 to 489) for
MASP-2. The intended age range for matching could al-
ways be respected. In the three largest diagnostic groups
(ALL, CNS-tumors, solid tumours), controls were used for
matching of two patients in ≤28% of patients.
MBL serum concentration in patients versus controls
In all six diagnostic groups, the median MBL serum con-
centration was higher in patients than in their age-matched
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controls. This difference was significant only for patients
with solid tumours (P = 0.008), which was confirmed in
sensitivity analysis (table 2).
MASP-2 serum concentration in patients versus
controls
In all six diagnostic groups, the median MASP-2 serum
concentration was higher in patients than in their age-
matched controls. This difference was significant in pa-
tients with ALL (P = 0.009), NHL (P = 0.037), and CNS-
tumors (P = 0.002). These differences were confirmed in
sensitivity analyses for ALL and CNS-tumors, while no
sensitivity analysis was required for NHL (table 3).
Table 1: Characteristics of patients and controls.
Patients potentially eligible, n = 718
Characteristic Excluded*, n = 346 Studied*, n = 372 P-value† Controls, n = 120 P-value‡
Sex 0.49 0.073
Female 137 (40%) 157 (42%) 62 (52%)
Male 209 (60%) 215 (58%) 58 (48%)
Age at diagnosis 0.12 <0.001
<4 years 107 (31%) 120 (32%) 63 (53%)
≥4 and <8 years 87 (25%) 79 (21%) 31 (26%)
≥8 and <12 years 68 (20%) 58 (16%) 14 (12%)
≥12 years 84 (24%) 115 (31%) 12 (10%)
Diagnostic group 0.002 -
Acute lymphoblastic leukemia 82 (24%) 114 (31%) -
Acute myeloid leukaemia 24 ( 7%) 29 ( 8%) -
Hodgkin’s disease 20 ( 6%) 23 ( 6%) -
Non-Hodgkin lymphoma 25 ( 7%) 41 (11%) -
Tumour of CNS 81 (23%) 46 (12%) -
Tumour outside CNS 114 (33%) 119 (32%) -
* Excluded were 37 patients with relapsed malignancies, 1 with second malignancy, and 308 because of missing serum; † P-values from exact Fisher’s and Fisher-
Freeman-Halton tests, comparison of excluded versus studied patients; ‡ P-values from exact Fisher’s and Fisher-Freeman-Halton tests, comparison of studied patients
versus controls.
Table 2: MBL Serum concentration in patients and age-matched controls.
Median (IQR) concentration [µg/L] Difference between patients and controlsDiagnostic groups Number of patients
Patients Controls Median Exact 95% CI* P-value†
Acute lymphoblastic leukaemia 114 2,976 (760 to 4,130) 2,423 (441 to 3,577) 473 –38 to 1,026 0.07
ALL sensitivity analysis‡ 82 2,976 (797 to 4,342) 2,150 (409 to 3,434) 680 15 to 1,338 0.05
Acute myeloid leukemia 29 2,230 (414 to 3,532) 2,016 (677 to 2,858) 154 –863 to 1,199 0.78
Hodgkin’s disease 23 3,323 (483 to 4,003) 2,445 (932 to 3,209) 870 –462 to 2,307 0.15
Non-Hodgkin lymphoma 41 2,649 (388 to 3,902) 2,445 (874 to 3,367) 200 –708 to 1,284 0.70
CNS-tumour 46 2,004 (459 to 3,817) 1,985 (441 to 3,091) 397 –468 to 1,414 0.37
CNS-tumour sensitivity analysis‡ 43 2,073 (506 to 3,969) 2283 (483 to 3,153) 458 –547 to 1,471 0.41
Solid tumour outside CNS 119 2,799 (790 to 4,126) 1,917 (450 to 3,339) 753 200 to 1,230 0.008
Solid tumour sensitivity analysis‡ 89 2,799 (1,002 to 4,197) 1,785 (383 to 3,199) 808 202 to 1,401 0.009
* Hodges-Lehmann exact 95% confidence interval; † two-sided exact Wilcoxon signed-rank test; ‡ by randomly eliminating one of the respective two patient-control pairs
when controls had been matched to two patients. No sensitivity analysis was made for groups in which no control had been matched to two patients, i.e., acute myeloid
leukemia, Hodgkin disease, and Non-Hodgkin lymphoma.
Abbreviations: MBL, mannan-binding lectin; 95% CI, 95% confidence interval; ALL, acute lymphoblastic leukemia; CNS, central nervous system; IQR, interquartile range.
Table 3: MASP-2 serum concentration in patients and age-matched controls.
Median (IQR) concentration [µg/L] Difference between patients and controlsDiagnostic groups Number of patients
Patients Controls Median Exact 95% CI* P-value†
Acute lymphoblastic leukaemia 114 406 (282 to 608) 317 (194 to 517) 95 24 to 157 0.009
ALL sensitivity analysis‡ 82 471 (298 to 633) 323 (211 to 514) 126 48 to 201 0.002
Acute myeloid leukaemia 29 356 (241 to 591) 325 (235 to 453) 52 –48 to 197 0.35
Hodgkin’s disease 23 365 (211 to 466) 290 (171 to 364) 49 –118 to 210 0.64
Non-Hodgkin lymphoma 41 361 (205 to 646) 293 (182 to 437) 131 8 to 277 0.037
CNS-tumour 46 463 (268 to 676) 296 (192 to 376) 178 72 to 295 0.002
CNS-tumor sensitivity analysis‡ 43 459 (269 to 673) 317 (201 to 415) 159 55 to 269 0.005
Solid tumour outside CNS 119 380 (236 to 552) 312 (192 to 453) 53 –11 to 117 0.10
Solid tumor sensitivity analysis‡ 89 382 (243 to 556) 325 (203 to 548) 34 –43 to 110 0.39
* Hodges-Lehmann exact 95% confidence interval. † two-sided exact Wilcoxon signed-rank test; ‡ by randomly eliminating one of the respective two patient-control pairs
when controls had been matched to two patients. No sensitivity analysis was made for groups in which no control had been matched to two patients, i.e., acute myeloid
leukemia, Hodgkin disease, and Non-Hodgkin lymphoma.
Abbreviations: MASP-2, mannan-binding lectin-associated serine protease-2; 95% CI, 95% confidence interval; ALL, acute lymphoblastic leukaemia; CNS, central nervous
system; IQR, interquartile range.
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Discussion
In this study, children with malignancies of all diagnostic
groups had higher median MBL and MASP-2 serum con-
centrations compared to age-matched controls. For MBL,
the differences were significant in patients with solid tu-
mours, and marginally for those with ALL. For MASP-2,
the differences were significant in patients with ALL, NHL
and CNS-tumours.
Regarding MBL, these results contrast with the finding that
children with ALL have more frequently low-producing
genotypes of the MBL2 gene compared to healthy adults
[11]. Methodological differences, i.e., genotype versus
phenotype, may at least partially explain this discrepancy.
We do not know of further reports on MBL in children with
cancer versus controls. In line with our results, MBL was
found to be higher in adult patients with colorectal cancer
[4] compared to healthy adults, and MBL was higher in
women with tumours of the reproductive system compared
to healthy controls with corresponding genotypes [6].
Regarding MASP-2, this is - to the best of our knowledge –
the first study comparing MASP-2 serum concentrations in
paediatric patients with malignancies versus age-matched
controls. In adult patients with colorectal cancer, higher
MASP-2 serum concentrations than in healthy adults have
as well been described [9]. Notably, high MASP-2 was as-
sociated with poor prognosis in adult colorectal cancer pa-
tients [9]. In contrast, high MASP-2 at diagnosis has been
reported to be associated with a better prognosis in children
with acute leukaemia and lymphoma [16].
This study cannot answer why MBL and MASP-2 serum
concentrations in children with certain malignancies are
higher than in controls. Several mechanisms are conceiv-
able. First, individual MBL or MASP-2 concentrations
might facilitate or hinder the development of malignancies.
Specifically, both high MBL and MASP-2 might act via in-
creased complement factor C5a in the tumour microenvir-
onment, which has been shown to enhance tumour growth
in a mouse model of cervical cancer [17]. Second, MBL
– but not MASP-2 – is an acute-phase component [18,
19] and might be increased during infections. Infections,
however, are frequent at diagnosis of leukemia, but not of
solid tumors [20], which makes this hypothesis less plaus-
ible. Third, MBL or MASP-2 might be increased as part of
the immunological response to malignancies themselves.
Fourth, MBL or MASP-2 might be actively expressed by
malignant cells, as has been shown for oesophageal squam-
ous cell carcinoma cells [10].
This study has several limitations. First, a selection bias
due to non-random availability of serum from diagnosis
might be possible. Such a bias could be excluded for sex
and age, but was confirmed for patients with CNS-tumors.
This bias did not distort the results in a relevant way, be-
cause the analyses were performed separately for each dia-
gnostic group. Second, this study focused only on pheno-
type (serum concentration), not genotype. Third, controls
were partially used for matching more than once, but the
sensitivity analyses addressing this issue confirmed the
main results. Despite the significant differences in age dis-
tribution between patient and controls, it was possible to al-
ways respect the predefined maximum relative age differ-
ence of 20% between patients and controls for matching.
The strengths of this study include the broad spectrum
of diagnoses, reflecting current epidemiological data [21],
the relatively large number of paediatric oncology patients
from four independent centers, and the use of age-matched
controls.
In conclusion, MBL serum concentration was significantly
higher in pediatric patients with solid tumours compared to
age-matched healthy controls, as was MASP-2 serum con-
centration in patients with ALL, NHL and CNS-tumours in
this study. These results may indicate a role of MBL and
MASP-2 in the initiation or progression of specific paedi-
atric cancers, while other mechanisms remain possible as
well. Larger, disease-specific studies are warranted for con-
firmation and for elucidation of the underlying mechan-
isms.
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